Human IL-1ra/IL-1F3 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB280
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
ELISA Capture (Matched Antibody Pair), Neutralization
Cited:
Array Development, ELISA Development, Immunocytochemistry, Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2A Clone # 10309
Product Specifications
Immunogen
E. coli-derived recombinant human IL‑1ra/IL-1F3
Arg26-Glu177
Accession # P18510
Arg26-Glu177
Accession # P18510
Specificity
Detects human IL‑1ra/IL-1F3 in ELISAs. In ELISAs, this antibody shows less than 0.2% cross-reactivity with recombinant mouse (rm) IL‑1ra and no cross-reactivity with rhIL‑1 alpha, rpIL‑1 alpha, rmIL‑1 alpha, rrIL‑1 alpha, rhIL‑1 beta, rpIL‑1 beta, rmIL‑1 beta, rrIL‑1 beta, rhIL‑1 RI, or rhIL‑1 RII.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IL-1ra/IL-1F3 Antibody
IL-1ra/IL-1F3 Inhibition of IL-1 alpha/IL-1F1-dependent Cell Proliferation and Neutralization by Human IL-1ra/IL-1F3 Antibody.
Recombinant Human IL-1ra/IL-1F3 (Catalog # 280-RA) inhibits Recombinant Human IL-1a/IL-1F1 (Catalog # 200-LA) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL-1a/IL-1F1 (50 pg/mL) activity elicited by Recombinant Human IL-1ra/IL-1F3 (50 ng/mL) is neutralized (green line) by increasing concentrations of Human IL-1ra/IL-1F3 Monoclonal Antibody (Catalog # MAB280). The ND50 is typically 10-20 µg/mL.Applications for Human IL-1ra/IL-1F3 Antibody
Application
Recommended Usage
Neutralization
Measured by its ability to neutralize IL‑1ra/IL‑1F3 inhibition of IL‑1 alpha/IL‑1F1-dependent proliferation in the D10.G4.1 mouse helper T cell line. Symons, J.A. et al. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 272. The Neutralization Dose (ND50) is typically 10-20 µg/mL in the presence of 50 ng/mL Recombinant Human IL‑1ra/IL‑1F3, 50 pg/mL Recombinant Human IL‑1 alpha/IL‑1F1.
Human IL-1ra/IL-1F3 Sandwich Immunoassay
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 3 reviews rated 4.7 using MAB280 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-1ra/IL-1F3
IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha. It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells, but reportedly will not block binding to the type II receptor on murine pre-B cell lines. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Currently, pre-clinical and clinical studies are underway to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.
Long Name
Interleukin 1 Receptor Antagonist
Alternate Names
DIRA, ICIL-1ra, IL-1F3, IL-1ra3, IL-1RN, IL1ra, IL1RN, MVCD4
Gene Symbol
IL1RN
UniProt
Additional IL-1ra/IL-1F3 Products
Product Documents for Human IL-1ra/IL-1F3 Antibody
Product Specific Notices for Human IL-1ra/IL-1F3 Antibody
For research use only
Loading...
Loading...
Loading...